Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
7.19
+0.21 (3.01%)
At close: Aug 13, 2025, 4:00 PM
7.29
+0.10 (1.39%)
Pre-market: Aug 14, 2025, 8:04 AM EDT
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $154.69M in the quarter ending June 30, 2025, with 22.12% growth. This brings the company's revenue in the last twelve months to $571.16M, up 25.35% year-over-year. In the year 2024, Amicus Therapeutics had annual revenue of $528.30M with 32.29% growth.
Revenue (ttm)
$571.16M
Revenue Growth
+25.35%
P/S Ratio
3.86
Revenue / Employee
$1,144,609
Employees
499
Market Cap
2.22B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 528.30M | 128.94M | 32.29% |
Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
FOLD News
- 12 days ago - Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200 - Seeking Alpha
- 13 days ago - Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 16 days ago - In NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of Data - GlobeNewsWire
- 24 days ago - Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 - GlobeNewsWire
- 5 weeks ago - SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm - PRNewsWire
- 7 weeks ago - Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan - GlobeNewsWire
- 7 weeks ago - U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts - GlobeNewsWire